



Company Overview

CohBar (NASDAQ:CWBR) is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine's Health Care 50
Nov 8 2018, 9:00 AM EST

CohBar Provides Update on CB4211 Clinical Trial
Nov 5 2018, 9:00 AM EST

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018
Oct 31 2018, 9:00 AM EDT

Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	159.24m
Last Price	\$3.75
52-Week	\$2.55 - \$10.789

11/12/2018 04:00 PM EST

Investor Relations

Jon Stern, COO
Investor Relations
T: (650) 446-7888 ext 111
jon.stern@cohbar.com

Management Team

Simon Allen, MBA
Chief Executive Officer

Kenneth C. Cundy, Ph.D.
Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA
Chief Financial Officer, Secretary and Treasurer

Jon L. Stern, MBA
Chief Operating Officer, Director

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.